Incannex Healthcare IXHL 深 滬
已收盤 07-31 16:00:00 美东时间
2.94
+0.010
+0.34%
華盛通- 最 高3.00
- 今 開2.96
- 成交量 7.16万股
- 最 低 2.82
- 昨 收 2.93
- 總市值 3517.58万
- 52周最高 27.687
- 市盈率 靜 --
- 換手率 0.60%
- 52周最低 2.49
- 委 比 93.80%
- 總股本 1196.46万
- 歷史最高 10800.00
- 量 比 0.84
- 振 幅 6.14%
- 歷史最低 2.40
- 每 手 1
- 風險率 5.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Incannex Begins Phase 2 DReAMzz Screening for IHL-42X
An announcement from Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) is n...
07-23 19:59
Incannex Healthcare Secures U.S. Patent For Compositions And Methods Of Treatment For Obstructive Sleep Apnea
The granted patent includes claims directed to the proprietary IHL-42X composition and its associated therapeutic methods for the treatment of Obstructive Sleep Apnea (OSA). The patent is expected to have a baseline expiry date of 9 July 2040 and the Company is exploring its eligibility for patent t...
06-25 20:05
Incannex Secures Key U.S. Patent for IHL-42X
The latest update is out from Incannex Healthcare Limited Sponsored ADR ( ($IXH...
06-25 19:57
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Inc. announced the USPTO has granted a key patent for its IHL-42X composition and therapeutic methods to treat Obstructive Sleep Apnea (OSA). The patent, set to expire in 2040, strengthens the company's intellectual property and supports long-term market exclusivity. IHL-42X, a novel oral therapy, addresses significant unmet needs in OSA treatment, with poor patient adherence to current options. The patent, combined with FDA F...
06-25 12:00
Incannex Healthcare Secures Major Non-Dilutive R&D Funding
The latest update is out from Incannex Healthcare Limited Sponsored ADR ( ($IXH...
06-10 20:01
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Alliance Global Partners Initiates Coverage On Incannex Healthcare with Buy Rating, Announces Price Target of $18
Alliance Global Partners analyst James Molloy initiates coverage on Incannex Healthcare (NASDAQ:IXHL) with a Buy rating and announces Price Target of $18.
06-08 22:05
Incannex Healthcare Q3 EPS $(0.35) Beats $(0.79) Estimate
Incannex Healthcare (NASDAQ:IXHL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.79) by 55.7 percent. This is a 94.35 percent increase over losses of $(6.19) per share
05-16 07:07
